**Author details**

Giulio Tarro1 , Moreno Paolini2 and Alessandra Rossi<sup>2</sup> \*

1 T. & L. de Beaumont Bonelli Foundation, Naples, Italy

2 Department of Pharmacy and Biotechnologies, Alma Mater Studiorum, University of Bologna, Bologna, Italy

\*Address all correspondence to: alessandra.rossi10@studio.unibo.it

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**117**

*Molecular Biology of Lung Cancer and Future Perspectives for Screening*

adenocarcinoma. Cancer Discovery.

[10] Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the

transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature.

[11] Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature.

[12] Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: A heterogeneous set of diseases. Nature Reviews. Cancer.

[13] Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nature Medicine. 2013;**19**(11):1469-1472

[14] Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Science Translational Medicine. 2010;**2**(62):62-93

[15] Guagnano V, Kauffmann A, Wöhrle S, Stamm C, Ito M, Barys L, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discovery.

[16] Ricordel C, Lespagnol A, Llamas-Gutierrez F, de Tayrac M, Kerjouan M,

2012;**2**(12):1118-1133

[9] Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell.

2014;**4**(4):415-422

2007;**131**(6):1190-1203

2007;**448**(7153):561-566

2004;**431**(7008):525-526

2014;**14**(8):535-546

*DOI: http://dx.doi.org/10.5772/intechopen.85334*

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians. 2013;**63**(1):11-30

[2] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians. 2011;**61**(2):69-90

biomarker for screening non-small-cell lung cancer and predicts poor prognosis.

[4] Zhao S, Jiang T, Zhang L, Yang H, Liu X, Jia Y, et al. Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis. Oncotarget.

[5] Reinersman JM, Johnson ML, Riely GJ, Chitale DA, Nicastri AD, Soff GA, et al. Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans. Journal of Thoracic

[6] Hudson AM, Wirth C, Stephenson NL, Fawdar S, Brognard J, Miller CJ. Using large-scale genomics data to identify driver mutations in lung cancer: Methods and challenges. Pharmacogenomics.

[7] Makinoshima H, Umemura S, Suzuki A, Nakanishi H, Maruyama A, Udagawa H, et al. Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in smallcell lung carcinoma. Cancer Research.

[8] Fernandez-Cuesta L, Plenker D, Osada H, Sun R, Menon R, Leenders F, et al. CD74-NRG1 fusions in lung

[3] Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel

Journal of Cancer Research and Clinical Oncology. 2012;**138**(12):

2016;**7**(24):36065-36073

Oncology. 2011;**6**(1):28-31

2015;**16**(10):1149-1160

2018;**78**(9):2179-2190

**References**

2045-2050

*Molecular Biology of Lung Cancer and Future Perspectives for Screening DOI: http://dx.doi.org/10.5772/intechopen.85334*
